Prognosis
Scanning for fat in Malaga.
View in browser
Bloomberg

Prognosis is exclusively for Bloomberg.com subscribers. As a loyal reader, you’re receiving a complimentary trial. If you’d like to continue receiving Prognosis, and gain unlimited digital access to all of Bloomberg.com, we invite you to subscribe now at the special rate of $149 for your first year (usually $299).

Hi, it’s Naomi in Berlin. I recently clipped a device to my heel to satisfy my vanity. More on that anon, but first...

Today’s must-reads

  • ‘Golden era’ of medication meets geopolitical uncertainty.

  • Sarepta reports second death of patient on its gene therapy

  • South Africa’s Ramaphosa to lead HIV fund replenishment. 

Scanning for fat

My ears perked up at the recent European Congress on Obesity in Malaga, Spain when a young newspaper reporter walked into the press room muttering something about “two kilos too much fat.” Apparently he’d gotten some surprising news from a body scan down in the presenters’ hall. 

Journalists have never been known for a lack of narcissism, so the rest of us trooped down, one by one, to see what the scanner would tell us about ourselves. 

Aminogram SAS, the French company marketing the device, had a booth close to Eli Lilly & Co. and Novo Nordisk, the two giant drugmakers currently duking it out for supremacy in the growing market for obesity medicines. Their ascendance is helping spur a market for medical devices as well, as companies develop diagnostic tools that can support prescriptions of the powerful new drugs. 

One preferred tool is something called a DEXA scan, a low-dose X-ray that measures the density of bones and assesses lean mass and fat. DEXA scanners are big enough to lie down on, and they’re not cheap — in London, a private scan can cost upwards of £150, while in New York they’re advertised online for $99 and more.  

Aminogram’s hand-held scanner relies instead on a method called bioimpedance, running a low-intensity electric current from the hand to the foot to measure the capacity of the body to resist the current. In practice, that meant I could hold a notched probe to my bare heel and conduct a measurement in a matter of seconds. 

There’s debate among doctors and scientists about the utility of bioimpedance measurements, with some arguing that one-time readings aren’t accurate enough to be the basis for treatment decisions for individual patients.  

“The idea is not to replace the DEXA scan,” says Etienne Gouraud, the Aminogram clinical project manager who helped measure me at the conference. “It’s just to compliment the DEXA scan, because in daily practice it’s very difficult to have a DEXA scan.” 

The use case would be regular monitoring to see how a patient is progressing, he says. And people shouldn’t read too much into a single scan suggesting fat mass of a couple of kilograms more than the target range, he said.

With all those caveats in place, I was curious to see if my own scan showed any hidden pitfalls. The results, however, were gratifyingly dull: I am extremely well-hydrated (shout-out to my fellow water-bottle-carrying Americans) but otherwise perfectly average on every measure. Accurate or not, that felt like a relief. — Naomi Kresge

What we’re reading

Older people are embracing vaccines, to their great benefit, the New York Times reports.

The new US vaccine panel raises questions about how RFK Jr. is defining conflicts of interest, STAT says.

One Utah dad's last wish was to stay alive until his daughter's birth, the Washington Post reports, highlighting rising rates of cancer among younger people.

Contact Prognosis

Health questions? Have a tip that we should investigate? Contact us at AskPrognosis@bloomberg.net.

Follow Us

Like getting this newsletter? There's more where that came from. Browse all our weekly and daily emails to get even more insights from your Bloomberg.com subscription.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Prognosis newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices